ADMS - Adamas Pharmaceuticals, Inc.
| Previous Close | 5.90 |
| Open | 5.94 |
| Bid | 5.00 x 1000 |
| Ask | 6.30 x 1000 |
| Day's Range | 5.80 - 6.06 |
| 52 Week Range | 3.35 - 12.57 |
| Volume | 450,849 |
| Avg. Volume | 658,488 |
| Market Cap | 163.803M |
| Beta (5Y Monthly) | 1.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.03 |
| Earnings Date | Jan 07, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.94 |
- ACCESSWIRE
SHAREHOLDER ALERT: ADMS FSCT EXC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / January 17, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
- ACCESSWIRE
ADMS EQUITY NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.; Important Deadline in Case - ADMS
NEW YORK, NY / ACCESSWIRE / January 17, 2020 / Rosen Law Firm announces the filing of a class action lawsuit on behalf of purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) between ...
- ACCESSWIRE
CLASS ACTION UPDATE for ADMS, MMSI and BZUN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / January 17, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- ACCESSWIRE
INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / January 17, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
NEW YORK, Jan. 17, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) Such.
- ACCESSWIRE
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, BZUN and EXC
NEW YORK, NY / ACCESSWIRE / January 16, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. A class action has commenced on behalf of certain shareholders in Adamas Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.
- ACCESSWIRE
ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / January 16, 2020 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (ADMS) between August 8, 2017, and September 30, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934. If you purchased Adamas securities, and/or would like to discuss your legal rights and options please visit Adamas Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.
- GlobeNewswire
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On March 4, 2019, Adamas revised previous prescription growth estimates for GOCOVRI, the Company’s primary product, warned of a continued slowdown in GOCOVRI prescriptions, and refused to predict GOCOVRI’s ability to achieve a sizeable market share.
- ACCESSWIRE
SHAREHOLDER ALERT: ADMS PRU MHK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / January 16, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
- ACCESSWIRE
ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 15, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. ("Adamas" ...
- ACCESSWIRE
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, FCAU and BZUN
NEW YORK, NY / ACCESSWIRE / January 15, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...
- GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Baozun, Inc. (BZUN), Adamas Pharmaceuticals, Inc. (ADMS), Cintas Corporation (CTAS), and Correvio Pharma Corp. (CORV). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
- ACCESSWIRE
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, WSG and CGC
NEW YORK, NY / ACCESSWIRE / January 15, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- ACCESSWIRE
SHAREHOLDER ALERT: ADMS FSCT HEXO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / January 14, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
- ACCESSWIRE
ADMS INVESTOR ALERT: Bernstein Liebhard Encourages Investors With Losses in ADMS Exceeding 20K to Contact the Firm and Reminds Investors of a Filing Deadline in a Securities Class Action Against Adamas Pharmaceuticals, Inc
NEW YORK, NY / ACCESSWIRE / January 14, 2020 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (ADMS) between August 8, 2017, and September 30, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934. If you purchased Adamas securities, and/or would like to discuss your legal rights and options please visit Adamas Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.
- ACCESSWIRE
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, AFI and PRU
NEW YORK, NY / ACCESSWIRE / January 14, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- GlobeNewswire
ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS
NEW YORK, Jan. 14, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August.
- ACCESSWIRE
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, ET and EXC
NEW YORK, NY / ACCESSWIRE / January 13, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...
- ACCESSWIRE
NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 13, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. ("Adamas" ...
- GlobeNewswire
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines
NEW YORK, Jan. 13, 2020 -- Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead.
- ACCESSWIRE
CLASS ACTION UPDATE for ADMS, WSG and XYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / January 13, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- GlobeNewswire
DEADLINE ALERT for HEXO, XYF, ADMS, EXC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
- GlobeNewswire
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif., Jan. 10, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two.
- ACCESSWIRE
CLASS ACTION UPDATE for ADMS, FSCT and ET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / January 10, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...